<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Reply to Unexpectedly higher mortality in non-type 1 narcolepsy: diagnostic heterogeneity or unmeasured confounders?

Simple item page
dc.contributor.authorSharafkhaneh, Amir
dc.contributor.authorDauvilliers, Yves
dc.contributor.authorBaHammam, Ahmed S.
dc.contributor.authorAzarian, Mehnaz
dc.contributor.authorThorpy, Michael
dc.contributor.authorHan, Fang
dc.contributor.authorSenel, Gulcin Benbir
dc.contributor.authorAksu, Murat
dc.contributor.authorRazjouyan, Javad
dc.date.accessioned2026-11-05T11:00:19Z
dc.date.issued2026
dc.description.issue1
dc.description.pages124
dc.description.sponsorshipSupported by seed funding from Baylor College of Medicine, Houston, Texas, United States, the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413), Michael E. DeBakey VA Medical Center, Houston, TX, United States, and a national institute of health (NIH), National Heart, Lung, and Blood Institute (NHLBI) K25 funding (#:1K25HL152006-01), and research grant from JAZZ Pharmaceutical to Dr. Razjouyan.
dc.description.volume22
dc.identifier.doi10.1007/s44470-026-00120-9
dc.identifier.issn1550-9389
dc.identifier.issn1550-9397
dc.identifier.urihttps://doi.org/10.1007/s44470-026-00120-9
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10391
dc.identifier.wosWOS:001830081200001
dc.language.isoen
dc.publisherSPRINGER INT PUBL AG
dc.relation.fundingBaylor College of Medicine, Houston, Texas, United States
dc.relation.fundingCenter for Innovations in Quality, Effectiveness and Safety
dc.relation.fundingMichael E. DeBakey VA Medical Center, Houston, TX, United States
dc.relation.fundingNational institute of health (NIH), National Heart, Lung, and Blood Institute (NHLBI) K25 funding
dc.relation.fundingJAZZ Pharmaceutical(Jazz Pharmaceuticals)
dc.relation.fundingCenter for Innovations in Quality, Effectiveness and Safety [CIN 13-413]
dc.relation.fundingNational institute of health (NIH), National Heart, Lung, and Blood Institute (NHLBI) K25 funding [1K25HL152006-01]
dc.relation.fundingJAZZ Pharmaceutical
dc.relation.hasversion10.1007/s44470-026-00120-9
dc.relation.ispartofJOURNAL OF CLINICAL SLEEP MEDICINE
dc.subjectMortality
dc.subjectNarcolepsy
dc.subjectHypersomnia
dc.subjectStimulant
dc.subjectOxybate
dc.subjectClinical Neurology
dc.subjectNeurosciences & Neurology
dc.titleReply to Unexpectedly higher mortality in non-type 1 narcolepsy: diagnostic heterogeneity or unmeasured confounders?
dc.typeLetter
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.issue1
oaire.citation.volume22
person.identifier.ridB-9037-2008
person.identifier.ridAFK-5542-2022
person.identifier.ridAAB-3101-2020

Files

Collections

WOS